Literature DB >> 7853482

Enhanced sensitivity to neutralizing antibodies in a variant of equine infectious anemia virus is linked to amino acid substitutions in the surface unit envelope glycoprotein.

R F Cook1, S L Berger, K E Rushlow, J M McManus, S J Cook, S Harrold, M L Raabe, R C Montelaro, C J Issel.   

Abstract

Serial passage of the prototype (PR) cell-adapted Wyoming strain of equine infectious anemia virus (EIAV) in fetal donkey dermal (FDD) rather than fetal horse (designated fetal equine kidney [FEK]) cell cultures resulted in the generation of a variant virus strain which produced accelerated cytopathic effects in FDD cells and was 100- to 1,000-fold more sensitive to neutralizing antibodies than its parent. This neutralization-sensitive variant was designated the FDD strain. Although there were differences in glycosylation between the PR and FDD strains, passage of the FDD virus in FEK cells did not reduce its sensitivity to neutralizing antibody. Nucleotide sequencing of the region encoding the surface unit (SU) protein from the FDD strain revealed nine amino acid substitutions compared with the PR strain. Two of these substitutions resulted in changes in the polarity of charge, four caused the introduction of a charged residue, and three had no net change in charge. Nucleotide sequence analysis was extended to the region of the FDD virus genome encoding the extracellular domain of the transmembrane envelope glycoprotein (TM). Unlike the situation with the FDD virus coding region, there were minor variations in nucleotide sequence between individual molecular clones containing this region of the TM gene. Although each clone contained three nucleotide substitutions compared with the PR strain, only one of these was common to all, and this did not affect the amino acid content. Of the remaining two nucleotide substitutions, only one resulted in an amino acid change, and in each case, this change appeared to be conservative. To determine if amino acid substitutions in the SU protein of FDD cell-grown viruses were responsible for the enhanced sensitivity to neutralizing antibodies, chimeric viruses were constructed by using an infectious molecular clone of EIAV. These chimeric viruses contained all of the amino acid substitutions found in the FDD virus strain and were significantly more sensitive to neutralizing antibodies than viruses from the parental (PR) molecular clone. These results demonstrated that sensitivity to neutralizing antibodies in EIAV can be conferred by amino acid residues in the SU protein. However, such amino acid substitutions were not sufficient to enhance cytopathogenicity, as the chimeric viruses did not cause excessive degenererative effects in FDD cells, as was observed with the parental FDD virus strain.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7853482      PMCID: PMC188739     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Production of equine infectious anemia antigen in a persistently infected cell line.

Authors:  W A Malmquist; D Barnett; C S Becvar
Journal:  Arch Gesamte Virusforsch       Date:  1973

2.  Antigenic drift of equine infectious anemia virus in chronically infected horses.

Authors:  Y Kono; K Kobayashi; Y Fukunaga
Journal:  Arch Gesamte Virusforsch       Date:  1973

3.  Isolation and comparative biochemical properties of the major internal polypeptides of equine infectious anemia virus.

Authors:  R C Montelaro; N Lohrey; B Parekh; E W Blakeney; C J Issel
Journal:  J Virol       Date:  1982-06       Impact factor: 5.103

4.  Equine infectious anemia virus, a putative lentivirus, contains polypeptides analogous to prototype-C oncornaviruses.

Authors:  B Parekh; C J Issel; R C Montelaro
Journal:  Virology       Date:  1980-12       Impact factor: 3.616

5.  Antiviral, anti-glycoprotein and neutralizing antibodies in foals with equine infectious anaemia virus.

Authors:  K O'Rourke; L E Perryman; T C McGuire
Journal:  J Gen Virol       Date:  1988-03       Impact factor: 3.891

6.  HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex.

Authors:  M Robert-Guroff; M Brown; R C Gallo
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

7.  Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients.

Authors:  R A Weiss; P R Clapham; R Cheingsong-Popov; A G Dalgleish; C A Carne; I V Weller; R S Tedder
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

8.  Evidence for host-cell selection of influenza virus antigenic variants.

Authors:  G C Schild; J S Oxford; J C de Jong; R G Webster
Journal:  Nature       Date:  1983 Jun 23-29       Impact factor: 49.962

9.  Sialic acids on the surface of caprine arthritis-encephalitis virus define the biological properties of the virus.

Authors:  D L Huso; O Narayan; G W Hart
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

10.  Lack of neutralizing antibodies to caprine arthritis-encephalitis lentivirus in persistently infected goats can be overcome by immunization with inactivated Mycobacterium tuberculosis.

Authors:  O Narayan; D Sheffer; D E Griffin; J Clements; J Hess
Journal:  J Virol       Date:  1984-02       Impact factor: 5.103

View more
  15 in total

1.  Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo.

Authors:  Y Ye; Z H Si; J P Moore; J Sodroski
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.

Authors:  Samantha Townsley; Yun Li; Yury Kozyrev; Brad Cleveland; Shiu-Lok Hu
Journal:  J Virol       Date:  2015-10-28       Impact factor: 5.103

3.  A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.

Authors:  J M Binley; R W Sanders; B Clas; N Schuelke; A Master; Y Guo; F Kajumo; D J Anselma; P J Maddon; W C Olson; J P Moore
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  Functional roles of equine infectious anemia virus Gag p9 in viral budding and infection.

Authors:  C Chen; F Li; R C Montelaro
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

5.  Characterization of primary isolate-like variants of simian-human immunodeficiency virus.

Authors:  J M Crawford; P L Earl; B Moss; K A Reimann; M S Wyand; K H Manson; M Bilska; J T Zhou; C D Pauza; P W Parren; D R Burton; J G Sodroski; N L Letvin; D C Montefiori
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

6.  Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex.

Authors:  T R Fouts; J M Binley; A Trkola; J E Robinson; J P Moore
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

7.  Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1.

Authors:  P J Klasse; J P Moore
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

8.  Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses.

Authors:  Yun Li; Bradley Cleveland; Igor Klots; Bruce Travis; Barbra A Richardson; David Anderson; David Montefiori; Patricia Polacino; Shiu-Lok Hu
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

9.  Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.

Authors:  Samantha Townsley; Zeinab Mohamed; Wenjin Guo; Jennifer McKenna; Brad Cleveland; Celia LaBranche; David Beaumont; Xiaoying Shen; Nicole L Yates; Abraham Pinter; Georgia D Tomaras; Guido Ferrari; David C Montefiori; Shiu-Lok Hu
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

10.  Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course.

Authors:  T Beaumont; A van Nuenen; S Broersen; W A Blattner; V V Lukashov; H Schuitemaker
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.